---
title: Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 2)
nct_id: NCT03806634
overall_status: UNKNOWN
sponsor: Taipei Veterans General Hospital, Taiwan
study_type: OBSERVATIONAL
primary_condition: Amyotrophic Lateral Sclerosis
countries: Taiwan
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03806634.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03806634"
ct_last_update_post_date: 2019-01-16
last_seen_at: "2026-05-12T07:22:59.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS (Part 2)

**Official Title:** Department of Physical Medicine & Rehabilitation, Taipei Veterans General Hospital

**NCT ID:** [NCT03806634](https://clinicaltrials.gov/study/NCT03806634)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 20
- **Lead Sponsor:** Taipei Veterans General Hospital, Taiwan
- **Conditions:** Amyotrophic Lateral Sclerosis
- **Start Date:** 2019-03-01
- **Completion Date:** 2020-09-01
- **CT.gov Last Update:** 2019-01-16

## Brief Summary

The research is aimed to asses the validity of the communication system improving the quality of life and the degree of sanctification of clinical patients and their caregiver.

## Eligibility

- **Minimum age:** 20 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Escorial revised criteria (Brooks et al., 2000),The diagnosis of ALS requires:

(A) the presence of:

* (A:1) evidence of lower motor neuron (LMN) degeneration by clinical, electrophysiological or neuropathologic examination (A:2) evidence of upper motor neuron (UMN) degeneration by clinical examination, and
* (A:3) progressive spread of symptoms or signs within a region or to other regions, as determined by history or examination, together with: (B) the absence of (B:1) electrophysiological or pathological evidence of other disease processes that might explain the signs of LMN and/or UMN degeneration, and (B:2) neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiological signs.

  * If they were Taiwanese and used traditional Chinese(Mandarin).
  * If they were older than age 20 years.

Exclusion Criteria:

* If they had been diagnosed with frontotemporal dementia, severe depression, or schizophrenia.
* If they cannot see the communication board after correction.
* If they cannot complete the questionnaire with researchers or family members help.
```

## Primary Outcomes

- **System Usability Scale** _(time frame: 2019.04.01~2019.06.30)_ — It consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. And also we can know the sanctification of the patient with ALS and their caregiver.

## Secondary Outcomes

- **Amyotrophic Lateral Sclerosis Specific Quality of Life Instrument-Revised, ALSSQOL-R** _(time frame: 2019.04.01~2019.06.30)_
- **Taiwanese Depression Questionnaire, TDQ** _(time frame: 2019.04.01~2019.06.30)_
- **Caregiver Burden Scale** _(time frame: 2019.04.01~2019.06.30)_

## Locations (1)

- Taipei Veterans General Hospital, Taipei, TW, Taiwan

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.taipei veterans general hospital|taipei|tw|taiwan` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03806634.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03806634*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*